Business Context and Reporting Period
Company: Pharming Group N.V.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: April 2, 2026
Reporting Period: Announcement of the filing of the Annual Report for the year ended December 31, 2025, and the corresponding Form 20-F.
Business Overview: A global biopharmaceutical company developing and commercializing innovative medicines (small molecules and biologics) for rare, debilitating, and life-threatening diseases. Headquartered in Leiden, the Netherlands, with significant U.S. operations.
Key Financial Metrics
The provided filing text is a press release announcing the availability of the 2025 Annual Report and Form 20-F. It does not contain specific financial data. Consequently, the following metrics are not available in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not provide comparative financial data or specific operational updates regarding material changes versus the prior period. It serves solely as a notification of the filing of the full annual report.
Guidance, Outlook, and Risks
Management Commentary: The company reaffirms its dedication to transforming the lives of patients with rare diseases through its portfolio of innovative medicines.
Guidance/Outlook: No specific financial guidance or operational outlook is provided in this text.
Risks/Contingencies: No specific risks or contingencies are detailed in this announcement.
Investor Verification Checklist
- Verify the full 2025 Annual Report and Form 20-F on the company website (annualreport.pharming.com) or the SEC website for detailed financial statements.
- Confirm the specific financial performance for the year ended December 31, 2025, as it is not included in this 6-K summary.
- Review the "Investors/Financial documents" section on Pharming.com for the complete set of audited financials.